Author(s)
Costa J1, Borges M2, Encarnação R3, Firmino H4, Gonçalves-Pereira M5, Lindeza P6, Sampaio F7, Santana I8, Sousa R2, Taipa R9, Verdelho A10, Silva Miguel L2
1Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal, 2Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal, 3Hospital de Magalhães Lemos E.P.E., Porto, Portugal, 4Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal, 5Nova Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal, 6Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal, 7Uppsala University, Uppsala, Sweden, 8Faculty of Medicine, University Hospital of Coimbra, Coimbra, Portugal, 9Centro Hospitalar Universitário do Porto, Hospital Santo António, Porto, Portugal, 10Centro Hospitalar Universitário Lisboa Norte EPE, Hospital de Santa Maria, Lisboa, Portugal
OBJECTIVES : Alzheimer's disease (AD) is a progressive, multifactorial neurodegenerative brain disorder. The pathophysiology initiates decades before the first symptoms. The progressive cognitive decline compromises patients’ behavioural and daily living skills. AD is the main cause of dementia with substantial humanistic and economic burden. We aimed to estimate the social costs and health losses associated with AD in patients aged ≥ 65 years in Portugal mainland during 2018. METHODS : The burden of disease and cost of illness were estimated using a prevalence-based approach. Burden of disease was measured in disability-adjusted life years (DALY), estimated as the sum of Years of Life Lost (YLL) due to premature mortality with Years Lost due to Disability (YLD). Costs of illness were estimated using a societal perspective and included medical and non-medical direct costs. The main sources of information were the hospital morbidity database; a Portuguese prevalence study that employed 10/66 Dementia Research Group algorithm; medicine consumption and price data; and the opinions of a panel of 7 experts of several medical specialities with regional representativeness. RESULTS : We estimated around 143,334 AD elderly patients in 2018 (7% of the population ≥65 years), extrapolating a 69% proportion of community-dwellers with dementia. In 2018 there were 7,538 deaths attributed to AD that resulted in the loss of 76,709 YLL. A total of 45,754 YLD were attributed to AD. The overall AD burden was 122,463 DALY. The estimated direct non-medical and medical costs attributable to AD in 2018 were €1.8 billion (€1.1 billion attributed to informal care) and €219 million, respectively. CONCLUSIONS : AD has a major socioeconomic impact, being responsible for 7% of the total YLL estimated for mainland Portugal. Prevalence estimates were based on community-dwellers data only and, therefore, maybe conservative. The total estimated cost reached €2 billion in 2018, equivalent to 1% of the Portuguese GDP.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSB188
Topic
Epidemiology & Public Health, Health Service Delivery & Process of Care
Topic Subcategory
Hospital and Clinical Practices
Disease
Geriatrics, Mental Health
